Hims & Hers Health (NYSE:HIMS) CFO Sells $1,943,389.47 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47. Following the completion of the sale, the chief financial officer directly owned 228,938 shares in the company, valued at $8,033,434.42. This represents a 19.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.99, for a total value of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Trading Up 2.8%

NYSE HIMS opened at $31.95 on Friday. The stock has a market capitalization of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40. The stock’s 50 day moving average price is $32.23 and its two-hundred day moving average price is $26.09. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period last year, the company earned $0.17 EPS. The company’s revenue was up 38.2% compared to the same quarter last year. As a group, analysts anticipate that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the company. QV Investors Inc. bought a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $7,771,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at about $11,520,000. Bank of New York Mellon Corp bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at about $46,220,000. Handelsbanken Fonder AB lifted its stake in Hims & Hers Health by 4.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock valued at $2,080,000 after purchasing an additional 2,300 shares during the last quarter. Finally, Valeo Financial Advisors LLC acquired a new stake in Hims & Hers Health in the 2nd quarter valued at about $225,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations and said the company’s strategy could improve patient access and affordability. He also discussed a potential AI health coach that could support medication adherence, creating a possible long-term technology catalyst. Hims & Hers rejects privacy allegations
• Positive Sentiment: Some investors continue to view the recent margin weakness as an opportunity, citing Hims & Hers’ 38.2% year-over-year revenue growth and potential expansion into testosterone, peptides, branded GLP-1 treatments and international markets. However, execution and profitability remain important hurdles. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Recent insider filings show sales by CFO Oluyemi Okupe, Deborah M. Autor and Soleil Boughton. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and several sales were intended to cover tax obligations from vested equity awards. Because insiders retained substantial positions, the filings are a limited bearish signal rather than clear evidence of weakening confidence. SEC insider transaction filing
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” while Needham raised its price target to $42 and maintained a Buy rating. The split view reflects strong sales growth but concerns about losses, margins and the GLP-1 business strategy.
• Negative Sentiment: The FTC litigation and new investigations by Kaplan Fox and Berger Montague add potential legal costs, compliance requirements and reputational risk. The investigations focus on alleged sharing of private health data, deceptive billing and difficult subscription cancellations, keeping regulatory uncertainty over the stock. Kaplan Fox investigation
• Negative Sentiment: Hims & Hers’ latest quarter showed a larger-than-expected loss of $0.37 per share versus the $0.05 consensus estimate, despite revenue exceeding expectations. The earnings miss and negative profitability metrics could limit the stock’s upside until margins improve.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HIMS shares. Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a research note on Tuesday, May 12th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research note on Friday, May 22nd. Needham & Company LLC raised their price objective on Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.